... in Italy we have developed a dual strategy: on one side in-licence local generic products; while on the other side ... increase our business development…
In Conversation
... Germany and the UK are the next strategic targets, but in those markets we will focus first on innovation.
... Andalusia’s hospitals have never been fully saturated throughout the entire pandemic, which has allowed us to be supportive of other regions, sending ventilators and receiving…
Italy has a key role to play in the EU objective of guaranteeing continuity of supply during emergencies.
My dream is that Italy, thanks to its infrastructure and location, can become the leading pharma manufacturing logistics hub for the Mediterranean region, joining northern Africa…
While Organon’s portfolio is meeting the needs of women, it is not enough. Governments and policymakers realise that they need to have tangible projects and approaches…
Accord recognises biosimilars as a future growth driver for the company. It is common sense as medicine moves to biologics and biologics move toward gene and…
I hope that the cooperation between packaging producers and pharmaceutical companies continues, especially in terms of co-development activity. Work is needed to improve access to these…
Brain health is not easy science because of the lack of biomarkers. However, with the right team, which I am convinced we have, a company of…
We truly believe that our R&D expertise, partnership appeal and focused go-to-market model make a recipe for success
The first of ADL Biopharma’s advantages is our pharma background, which guarantees the highest level of quality and reliability ...
In all of Kyowa Kirin’s daily activities we have a focus on people, both internal and external, and our aim is always to make people smile,…
